Media stories about Teva Pharmaceutical Industries (NYSE:TEVA) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.4438731270668 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
Several research firms have weighed in on TEVA. BidaskClub downgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Citigroup downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $32.00 to $19.00 in a research report on Wednesday, August 16th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday, September 11th. Royal Bank Of Canada increased their price target on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the stock an “underperform” rating in a research report on Sunday, November 5th. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, September 11th. Seven research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $21.65.
Shares of Teva Pharmaceutical Industries (TEVA) traded up $1.06 during trading hours on Friday, hitting $16.06. 37,014,692 shares of the company’s stock were exchanged, compared to its average volume of 20,490,736. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $38.31. The stock has a market cap of $15,240.00, a PE ratio of 3.46 and a beta of 0.55. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.085 dividend. The ex-dividend date is Monday, November 27th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.12%. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/12/09/teva-pharmaceutical-industries-teva-receives-daily-news-impact-score-of-0-13.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.